EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

A multicenter, prospective, non‐interventional real‐world study to assess the effectiveness of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal cancer

Chenyu Mao iD, Ye He, Nong Xu, Haijiao Yan, Ningling Zhang, Gang Cheng, Hua Jiang, Minbin Chen, Yong Chen iD, Xiaoguang Wang, Yulan Gu, Peng Shen und 10 weitere

Immunity, Inflammation and Disease · 2024

DOI: 10.1002/iid3.1348 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Immunity, Inflammation and Disease, 2024. Verfasst von Chenyu Mao und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Fluorouracil, Gastrointestinal Neoplasms, Neutropenia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Hengrui Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mecapegfilgrastim, a long‐acting granulocyte‐colony stimulating factor has been approved for reducing the incidence of infection, particularly febrile neutropenia (FN), in China.

Objective

We conducted a multicenter prospective observational study to examine the safety and effectiveness of mecapegfilgrastim in preventing neutropenia in gastrointestinal patients receiving the chemotherapy, including S‐1/capecitabine‐based regimens or the fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI)/fluorouracil, leucovorin, and oxaliplatin (FOLFOX)/fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) regimens.

Method

Five hundred and sixty‐one gastrointestinal patients from 40 sites across China, between May 2019 and November 2021, were included. The administration of mecapegfilgrastim was prescribed at the discretion of local physicians.

Results

The most common adverse drug reactions (ADRs) of any grade for all patients was increased white blood cells (2.9%). Grade 3/4 ADRs were observed for anemia (0.2%), decreased white blood cells (0.2%), and decreased neutrophil count (0.2%). Among the 116 patients who received S‐1/capecitabine‐based chemotherapy throughout all cycles, ADRs of any grade included anemia (1.7%), myalgia (0.9%), and increased alanine aminotransferase (0.9%). No grade 3/4 ADRs were observed. In 414 cycles of patients who underwent S‐1/capecitabine‐based regimens, only one (0.2%) cycle experienced grade 4 neutropenia. In the FOLFIRINOX, FOLFOXIRI, and FOLFOX chemotherapy regimens, grade 4 neutropenia occurred in one (2.7%) of 37 cycles, four (4.7%) of 85 cycles, and two (1.2%) of 167 cycles, respectively.

Conclusion

In a real‐world setting, mecapegfilgrastim has proven effective in preventing severe neutropenia in gastrointestinal patients following chemotherapy. This includes commonly used moderate or high‐risk FN regimens or regimens containing S1/capecitabine, all of which have demonstrated favorable efficacy and safety profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsFluorouracilGastrointestinal NeoplasmsNeutropeniaPolyethylene GlycolsAdultAgedFemaleHumansMaleMiddle AgedChinaIrinotecanLeucovorinOxaliplatinProspective StudiesRecombinant ProteinsGranulocyte Colony-Stimulating Factor

Stichwörter der Autor:innen

gastrointestinalmecapegfilgrastimneutropeniareal‐world

Substanzen

FluorouracilIrinotecanLeucovorinOxaliplatinPolyethylene Glycolspegylated granulocyte colony-stimulating factorRecombinant ProteinsGranulocyte Colony-Stimulating Factor

Autor:innen und Institutionen

  • Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China.
  • Department of Oncology, The First People's Hospital of Changzhou, Changzhou, China.
  • Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
  • Department of Oncology, Bozhou People's Hospital, Bozhou, China.
  • Department of Oncology, The Second People's Hospital of Changzho, Changzhou, China.

ORCID-Profile: Chenyu Mao, Yong Chen, Zhe Yang, Shukui Qin

Förderung

  • Jiangsu Hengrui Medicine

Zitieren

APA

Mao, C., He, Y., Xu, N., Yan, H., Zhang, N., Cheng, G., Jiang, H., Chen, M., Chen, Y., Wang, X., Gu, Y., Shen, P., Zhang, G., Yan, J., Yang, Z., Ding, L., Han, Z., Wang, Z., Zhang, J., …, & Qin, S. (2024). A multicenter, prospective, non‐interventional real‐world study to assess the effectiveness of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal cancer. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.1348

Vancouver

Mao C, He Y, Xu N, Yan H, Zhang N, Cheng G, et al. A multicenter, prospective, non‐interventional real‐world study to assess the effectiveness of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal cancer. Immunity, Inflammation and Disease. 2024. doi:10.1002/iid3.1348

BibTeX
@article{Mao2024,
  author = {Mao, Chenyu and He, Ye and Xu, Nong and Yan, Haijiao and Zhang, Ningling and Cheng, Gang and Jiang, Hua and Chen, Minbin and Chen, Yong and Wang, Xiaoguang and Gu, Yulan and Shen, Peng and Zhang, Guifang and Yan, Jun and Yang, Zhe and Ding, Lifang and Han, Zhengxiang and Wang, Zhanggui and Zhang, Junqi and Zheng, Weie and Wang, Jufeng and Qin, Shukui},
  title = {A multicenter, prospective, non‐interventional real‐world study to assess the effectiveness of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal cancer},
  journal = {Immunity, Inflammation and Disease},
  year = {2024},
  doi = {10.1002/iid3.1348}
}
Kostenlos starten →